cagrilintide tirzepatide combination trial Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial? CagriSema: Strong Obesity Data, but – cagrilintide tirzepatide combination study Dosage:

Medically Reviewed by: Dr Kanika Raina, BDS, MBA (Hospital & Healthcare Management) Last reviewed: February 2026 References: Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K

It works by targeting melanocortin receptors influencing skin pigmentation and stimulating neurological pathways associated with sexual desire

In Canada, all of these weight loss medications can be used in adult patients with an initial body mass index (BMI) of: 30 Kg/m2 or greater, or 27 Kg/m2 or greater in the presence of at least one weight-related comorbidity (ie, high blood pressure, type 2 diabetes, high cholesterol, fatty liver, sleep apnea, etc) To find out if any of these agents are covered on your benefits plan, use each of the drug identification numbers (DIN) listed below each medication name to check with your benefits plan or pharmacy

The combined effect produces a stronger, longer GH pulse than either peptide alone